FDA approves Northera to treat neurogenic orthostatic hypotension

FDA approves Northera to treat neurogenic orthostatic hypotension

The U.S. Food and Drug Administration today approved Northera capsules (droxidopa) for the treatment of neurogenic orthostatic hypotension (NOH). NOH is a rare, chronic and often debilitating drop in blood pressure upon standing that is associated with 

8
Like
Save

Comments

Write a comment

*